A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). (Q33416569)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). |
scientific article |
Statements
1 reference
A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). (English)
1 reference
Huyen Tran
1 reference
Tim Brighton
1 reference
Andrew Grigg
1 reference
Simon McRae
1 reference
Joanna Dixon
1 reference
Daniel Thurley
1 reference
Maher K Gandhi
1 reference
Matt Truman
1 reference
Paula Marlton
1 reference
John Catalano
1 reference
11 July 2014
1 reference
1 reference
167
1 reference
243-251
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference